Tidal Investments LLC increased its position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 22.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 493,507 shares of the company’s stock after acquiring an additional 91,492 shares during the period. Tidal Investments LLC owned approximately 0.12% of Zoetis worth $35,463,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also bought and sold shares of ZTS. National Pension Service raised its position in shares of Zoetis by 9.6% in the second quarter. National Pension Service now owns 839,875 shares of the company’s stock worth $60,353,000 after buying an additional 73,785 shares in the last quarter. WINTON GROUP Ltd purchased a new position in Zoetis during the second quarter worth about $223,000. Engineers Gate Manager LP grew its position in Zoetis by 3,551.3% during the second quarter. Engineers Gate Manager LP now owns 107,678 shares of the company’s stock worth $7,738,000 after buying an additional 104,729 shares in the last quarter. SVB Wealth LLC increased its stake in Zoetis by 14.3% in the 2nd quarter. SVB Wealth LLC now owns 27,385 shares of the company’s stock worth $1,968,000 after acquiring an additional 3,426 shares during the last quarter. Finally, Integrated Wealth Concepts LLC raised its holdings in shares of Zoetis by 7.0% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 8,044 shares of the company’s stock valued at $578,000 after acquiring an additional 527 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on ZTS shares. Citigroup cut their price objective on Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. BNP Paribas Exane dropped their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a research report on Tuesday, August 11th. UBS Group cut their price target on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a research note on Friday, August 7th. Weiss Ratings lowered shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. Finally, Argus restated a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Eight analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $101.08.
Zoetis Stock Down 0.2%
Shares of ZTS opened at $73.39 on Thursday. The firm has a market cap of $30.33 billion, a P/E ratio of 12.09, a P/E/G ratio of 1.72 and a beta of 0.73. The stock has a 50 day simple moving average of $75.63 and a two-hundred day simple moving average of $92.49. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. Zoetis Inc. has a 1 year low of $71.00 and a 1 year high of $152.00.
Zoetis (NYSE:ZTS – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. During the same period last year, the firm posted $1.76 earnings per share. The business’s revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, analysts forecast that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.
Zoetis Profile
Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity.
The company’s product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services.
Read More
- Five stocks we like better than Zoetis
- Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
- GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus
- Casey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality Retailer
- Sovereign AI: Palantir and Nebius Cut the Cloud Cord
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
